In subsequent randomized trials, palbociclib, in combination with endocrine therapy, has been reported to prolong progression-free survival 5, 7, 8, leading to its approval in patients with metastatic HR-positive/HER2-negative breast cancer 34. Here, ERBB2 is linked to breast carcinoma.